“Deucravacitinib Long-Term Efficacy Through 4 years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program”, J of Skin, vol. 8, no. 4, p. s408, Jul. 2024, doi: 10.25251/skin.8.supp.408.